Loading patent…
AssigneesAssociation pour l'Essor de la Transfusion Sanguine dans la Region du Nord, Biotest Pharma GmbH
InventorsRoland Beliard, Ulf Bethke, Dominique Bourel, Ahmed Bouzidi, Herve Broly, Peter Byrne, Magali Holuigue, Michael Kloft, Detlef Rohm
Estimating the term…
The invention relates to 2 human monoclonal antibodies of sub-classes IgG1 and IgG3, against the Rhesus D antigen and to a pharmaceutical composition containing a mixture of the said antibodies, more particularly intended for the prophylaxis of the haemolytic disease of the newborn. The invention also relates to the heterohybridoma cell lines that produce these antibodies, which are filed with the "Deutsche Sammlung von Mikroorganismen und Zellkulturen" under accession numbers DSM AC 2039 and DSM AC 2040.
A human/mouse heterohybridoma cell line having deposit number DSM ACC 2039.
A human/mouse heterohybridoma cell line having deposit number DSM ACC 2040.
A pharmaceutical composition for the prophylaxis of the haemolytic disease of the newborn which comprises a mixture of human monoclonal anti-RhD antibodies, said mixture including at least a first monoclonal antibody of sub-class IgG1 produced by the heterohybridoma cell line DSM ACC 2039 and a second monoclonal antibody of sub-class IgG3 produced by the heterohybridoma cell line DSM ACC 2040, wherein:
Dependencies are inferred from the claim text.